🇮🇳 India Stock Screener ← Switch market ⚡ HerAI

Wanbury Limited WANBURY NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.wanbury.com
Company Profile ↓
₹244.75
-8.08% 1Y
Mkt Cap₹855.82 Cr
P/E15.02
P/B5.07
52W High₹344.75
52W Low₹163.34
Book Value₹48.32
EPS (TTM)₹16.30

Company Overview

Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India and internationally. It offers formulations for anti-infectives, pain and analgesics, gastroenterology, rheumatology, respiratory, gynecology, and central nervous system, as well as for vitamins, minerals, and nutrition. The company also provides API products for antidiabetics, antidepressants, anti-histaminic, anaesthetic, anti-inflammatory, anti-coagulant, GERD, and gastric ulcer therapy, as well as antitussives and analgesics. Its API portfolio includes Metformin Hcl, Sertraline Hcl, Tramadol Hcl, Mefenamic Acid , Metformin Hcl DC, Diphenhydramine Citrate, Paroxetine, Diphenhydramine Hcl, and Anaesthetic API. The company was formerly known as Pearl Organics Limited and changed its name to Wanbury Limited in 2004. Wanbury Limited was founded in 1988 and is headquartered in Navi Mumbai, India.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 45.8%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 28.4%.

Consistent Profit Growth

Net profit has compounded at 245.4% per year over the last five years.

Reasonable Valuation

Trades at a P/E of 15.0, below the sector median of 42.5.

Recent Developments

  • Mar 2026 Revenue of ₹650.27 Cr (+8.5% YoY); net profit ₹66.13 Cr.
  • Trailing 12 Months Year-on-year growth — revenue -19.2%, earnings +116.6%.
  • 5-Year Trend Long-term compounding — revenue CAGR 9.3%, profit CAGR 245.4%.

Growth & Price Performance

Compounded Sales Growth

5 Years:9.29%
1 Year:-19.20%

Compounded Profit Growth

5 Years:245.39%
1 Year:116.62%

Stock Price Performance

1 Year:-8.08%
6 Months:-0.14%
3 Months:-4.38%
1 Month:-0.57%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 45% of range
₹163.34 ₹344.75
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)36.79 · Neutral
Price Performance
1M-0.57%
3M-4.38%
6M-0.14%
1Y-8.08%
Valuation vs Sector

P/E of 15.02 is below the sector median of 42.46 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Strong return on equity of 45.8%.
  • Healthy ROCE of 28.4%.
  • Profit CAGR of 245.4% over 5 years.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading 29.0% below its 52-week high.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
15.02
Industry PE
42.46
Forward P/E est.
7.51
PEG Ratio
-
Book Value
₹48.32
Price to Book
5.07
P/S
2.30
EV/EBITDA
11.35
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
9.29%
Profit 5Y
245.39%
Revenue (YoY)
-19.20%
Earnings (YoY)
116.62%

Profitability & Returns

ROCE
28.35%
ROE
45.78%
ROA
12.78%
Profit Margin
-25.90%
Op Margin
5.49%
Gross Margin
48.25%
EPS (Latest Qtr)
₹6.27
EPS (TTM)
₹16.30

Balance Sheet & Liquidity

Debt/Equity
1.55
Quick Ratio
0.93
Current Ratio
1.19
Debt
₹224.37 Cr
Total Assets
₹517.67 Cr
Current Assets
₹238.56 Cr
Working Capital
₹37.52 Cr

Ownership

Promoter Holding
51.31%
Chg in Prom Hold
-0.04%
FII / Inst Holding
2.08%
Chg in FII Hold
-0.00%

Financial Snapshot

Enterprise Value
₹855.82 Cr
Total Revenue (TTM)
₹371.93 Cr
EBITDA
₹-74.38 Cr
Free Cash Flow
₹-28.08 Cr
Operating Cash Flow
₹31.53 Cr
Shares Outstanding
₹3.50 Cr
Gross Margin
48.25%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 WANBURY Wanbury Limited NSEPHARMA 244.75 15.02 ₹855.82 Cr 0.00% 28.35% 45.78% 9.29% 245.39%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,864.90 37.04 ₹4.47 L Cr 0.85% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 9,488.00 86.17 ₹2.52 L Cr 0.31% 18.96% 15.32% 10.98% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,930.00 78.88 ₹1.88 L Cr 0.77% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,967.00 61.87 ₹1.29 L Cr 0.23% 19.20% 20.48% 14.85% 33.34%
6 LENSKART Lenskart Solutions Limited NIFTY_MIDNSEPHARMA 693.90 184.55 ₹1.20 L Cr 0.00% 7.21% 5.65% 35.38% 66.99%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,127.40 25.11 ₹1.12 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,363.10 32.72 ₹1.10 L Cr 0.94% 14.86% 11.27% 7.23% 11.45%
9 LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA 1,937.00 95.65 ₹1.05 L Cr 0.12% 19.53% 16.77% 3.77% 4.00%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 117.00 Cr124.00 Cr126.00 Cr133.00 Cr146.00 Cr144.00 Cr146.00 Cr139.00 Cr131.00 Cr--172.00 Cr163.18 Cr160.06 Cr162.45 Cr164.58 Cr
Cost of Revenue -----------84.32 Cr75.35 Cr67.06 Cr68.80 Cr65.30 Cr
Gross Profit -----------87.68 Cr87.84 Cr93.00 Cr93.65 Cr99.27 Cr
Operating Expenses 120.00 Cr118.00 Cr119.00 Cr119.00 Cr133.00 Cr127.00 Cr124.00 Cr121.00 Cr120.00 Cr--61.43 Cr67.04 Cr70.93 Cr70.70 Cr72.65 Cr
Operating Income -6.00 Cr3.00 Cr3.00 Cr11.00 Cr10.00 Cr14.00 Cr18.00 Cr15.00 Cr8.00 Cr--26.25 Cr20.80 Cr22.08 Cr22.95 Cr26.62 Cr
EBITDA -3.00 Cr6.00 Cr6.00 Cr14.00 Cr13.00 Cr17.00 Cr21.00 Cr18.00 Cr11.00 Cr--31.47 Cr24.79 Cr25.98 Cr26.86 Cr26.45 Cr
Interest Expense 3.00 Cr4.00 Cr7.00 Cr8.00 Cr6.00 Cr8.00 Cr8.00 Cr7.00 Cr8.00 Cr--9.04 Cr7.54 Cr7.12 Cr7.26 Cr8.06 Cr
Pretax Income -7.00 Cr-1.00 Cr-3.00 Cr1.00 Cr5.00 Cr7.00 Cr10.00 Cr34.00 Cr1.00 Cr--19.05 Cr13.61 Cr15.16 Cr15.87 Cr15.17 Cr
Tax Provision 21.00 L-25.00 L-24.00 L-11.00 L30.00 L-14.00 L-034.00 L0---1.20 Cr11.53 L-1.93 L10.61 L-6.53 Cr
Net Income -7.00 Cr-1.00 Cr-3.00 Cr1.00 Cr5.00 Cr7.00 Cr10.00 Cr34.00 Cr1.00 Cr--20.26 Cr13.49 Cr15.18 Cr15.76 Cr21.70 Cr
Diluted EPS -2.21-0.27-1.000.311.432.253.1410.270.32--5.983.954.584.516.27

Profit & Loss (Annual)

Figures in INR.

Metric Sep 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 661.00 Cr250.00 Cr420.00 Cr432.00 Cr370.00 Cr391.00 Cr367.00 Cr392.00 Cr-498.18 Cr574.48 Cr599.51 Cr650.27 Cr
Cost of Revenue ---------309.02 Cr310.14 Cr294.47 Cr276.51 Cr
Gross Profit ---------189.15 Cr264.34 Cr305.04 Cr373.76 Cr
Operating Expenses 637.00 Cr228.00 Cr387.00 Cr414.00 Cr438.00 Cr375.00 Cr344.00 Cr374.00 Cr-177.29 Cr207.13 Cr242.04 Cr281.32 Cr
Operating Income 2.00 Cr16.00 Cr24.00 Cr9.00 Cr-78.00 Cr6.00 Cr13.00 Cr8.00 Cr-11.86 Cr57.21 Cr63.01 Cr92.44 Cr
EBITDA 25.00 Cr21.00 Cr33.00 Cr19.00 Cr-68.00 Cr16.00 Cr23.00 Cr18.00 Cr-23.49 Cr98.55 Cr79.91 Cr104.09 Cr
Interest Expense 48.00 Cr19.00 Cr32.00 Cr36.00 Cr31.00 Cr40.00 Cr33.00 Cr23.00 Cr-21.39 Cr29.18 Cr36.95 Cr29.98 Cr
Pretax Income -125.00 Cr4.00 Cr-7.00 Cr62.00 Cr-32.00 Cr-25.00 Cr65.00 Cr-12.00 Cr--10.29 Cr56.34 Cr29.55 Cr59.80 Cr
Tax Provision -2.50 Cr1.12 Cr-062.00 L32.00 L25.00 L0-24.00 L-10.90 L38.10 L-97.94 L-6.33 Cr
Net Income -128.00 Cr3.00 Cr-7.00 Cr62.00 Cr-32.00 Cr-25.00 Cr64.00 Cr-13.00 Cr--10.40 Cr55.96 Cr30.53 Cr66.13 Cr
Diluted EPS -63.951.60-3.5826.71-13.49-10.4825.79-5.0425.21-3.1816.898.98-

Balance Sheet (Annual)

Figures in INR.

Metric Sep 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 406.00 Cr396.00 Cr388.00 Cr412.00 Cr273.00 Cr286.00 Cr279.00 Cr289.00 Cr-303.52 Cr343.12 Cr413.92 Cr517.67 Cr
Current Assets ---------123.79 Cr158.61 Cr193.44 Cr238.56 Cr
Cash & Equivalents ---------1.49 Cr3.40 Cr4.06 Cr1.61 Cr
Inventory ---------21.99 Cr36.02 Cr37.68 Cr50.63 Cr
Receivables ---------68.98 Cr88.76 Cr114.16 Cr143.28 Cr
Total Liabilities ---------336.34 Cr315.18 Cr354.65 Cr373.22 Cr
Current Liabilities ---------320.03 Cr210.70 Cr174.61 Cr201.04 Cr
Long Term Debt ---------082.00 Cr160.29 Cr147.15 Cr
Total Debt 389.00 Cr381.00 Cr362.00 Cr300.00 Cr250.00 Cr260.00 Cr190.00 Cr192.00 Cr-108.58 Cr115.80 Cr176.91 Cr224.37 Cr
Total Equity -192.00 Cr-194.00 Cr-189.00 Cr-153.00 Cr-184.00 Cr-209.00 Cr-143.00 Cr-156.00 Cr--32.82 Cr27.94 Cr59.27 Cr144.45 Cr
Shares Outstanding ---------3.27 Cr3.27 Cr3.28 Cr3.49 Cr

Cash Flows (Annual)

Figures in INR.

Metric Sep 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 68.00 Cr40.00 Cr43.00 Cr43.00 Cr32.00 Cr30.00 Cr44.00 Cr17.00 Cr-19.80 Cr4.70 Cr26.20 Cr31.53 Cr
Investing Cash Flow -6.00 Cr-5.00 Cr-20.00 Cr-13.00 Cr-1.00 Cr-3.00 Cr64.00 Cr8.00 Cr--8.84 Cr-16.63 Cr-51.17 Cr-56.40 Cr
Financing Cash Flow -71.00 Cr-30.00 Cr-28.00 Cr-27.00 Cr-33.00 Cr-27.00 Cr-108.00 Cr-17.00 Cr--31.99 Cr13.87 Cr25.63 Cr22.42 Cr
Capital Expenditure -12.00 Cr-5.00 Cr-21.00 Cr-14.00 Cr-2.00 Cr-5.00 Cr-8.00 Cr-5.00 Cr--12.63 Cr-17.42 Cr-49.03 Cr-59.61 Cr
Free Cash Flow 56.00 Cr35.00 Cr22.00 Cr29.00 Cr30.00 Cr25.00 Cr36.00 Cr12.00 Cr-7.17 Cr-12.73 Cr-22.82 Cr-28.08 Cr
Net Change in Cash -9.00 Cr5.00 Cr-5.00 Cr3.00 Cr-2.00 Cr-0-07.00 Cr--21.03 Cr1.94 Cr66.04 L-2.45 Cr

Ratios (Annual)

Figures in %.

Metric Sep 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % ---------38.0%46.0%50.9%57.5%
Operating Margin % 0.3%6.4%5.7%2.1%-21.1%1.5%3.5%2.0%-2.4%10.0%10.5%14.2%
Net Margin % -19.4%1.2%-1.7%14.4%-8.6%-6.4%17.4%-3.3%--2.1%9.7%5.1%10.2%
ROE % 66.7%-1.5%3.7%-40.5%17.4%12.0%-44.8%8.3%-31.7%200.3%51.5%45.8%
ROCE % ----------71.9%43.2%26.3%29.2%

Shareholding Pattern

Insiders
51.31%
Institutions
2.08%
Public Float
4.27%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for WANBURY

Google News ue, 21 Jul 2026

Wanbury Shares Tank 7% In Trade — What's Spooking Investors? - NDTV Profit

<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxPbzd0UHN0SHhIWWR0Ty1jcjdFT1VDNDVKa1BBZG85SGx5WXh4LVB5WWlhajN1dVg5Smc4aVVWN0dhcVM4dGd4Zzl3ZzBFSjM2Vjg5MVVqek54VUEyNEdBM202bnVtemZva2ZsdXRPcXhLYTlyTmhEQk9xWG5WdWgzOGpaMC1mSVJXYXdPb0…

Google News Mon, 20 Jul 2026

Buzzing Stock: Wanbury declines 5% after USFDA inspection; Rallis India slips 2% post Q2 earnings - TradingView

<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxOaTlWV1hPXzIzWklWWE1CMGJUTTFCSzVFTkVYZTJ6RjNBSVVQYzRMV3dfeHRWem9TNnRoZE1BeWJ4U2hHMEJUQk9vUVgtRkdTdGFBMVBOVVNfXzZodUc0aFd2clpkZURnWHVSTGpsWlpCMjNMMW1KQXBHdVRIVU9EaWx4VlpXLUZDbHFTYk…

Google News hu, 27 Aug 2026

Wanbury Ltd. Key Financial Ratios – Valuation, Profitability & More - Value Research

<a href="https://news.google.com/rss/articles/CBMifEFVX3lxTE92V0U2YnRrQmUyT193MWVKeWZHdWg5TndlRDVmRlN0SEV0Vlotb1dENVJfMjl2TjQ5ZjZhX0loX3p2dEFGMjItMVJYWlF2MjBodEJrUHl2dnh5al9xOTJiTjhqNk1PcnM4YklaTkJzajlEVGxOOW1DaG52VnA?oc=5" target="_blank">…

Google News Sat, 24 Jan 2026

Wanbury Limited's (NSE:WANBURY) 25% Dip In Price Shows Sentiment Is Matching Earnings - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi4AFBVV95cUxPSFJ3S09RYW9aWnZhNVNzdzRzbThCWXlGVUxSTVRwNWhJeUZjX1h4eWFOU0pGUjJvSnQ5a3o1Sk9nNEJySWh0ZUlsdk9hWjYwM0hDZDdPUW1xQWpTNDhwTmlqT1l5QkNlU2ROSEdxX1FaVjJKRmt5UmUwYm1ublNiMFJrWWREemdVR004ZW…

Google News Wed, 15 Jul 2026

Wanbury Ltd Spurts 3.27% - Business Standard

<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxOYkNPdVU3X0JHdGp1OE5CRlQ0dktvUng0VXpUZnVSZi1SaHFYUTd3R0VuSlljVkZPSUlNT1ppN24yMlZHLUhFbW5GTTdsRDRiX3JNRElrb3lzQ0VRaUlLZUFSTUFXc08xUGlNVmE4MElSYlRUOEw5cHJnNVUzcVA5VVN0ZVc4b1pXbFA2dE…

Google News Fri, 28 Aug 2026

Wanbury sets book closure from Sep 18 to 24 for 38th AGM - scanx.trade

<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxNZlhNdkdvX05YN3lmMk52bUlYZnpSbWVYVF8za2szUlVoQ3V1TlZGa0dCYlgxMXgzb21YS1l6S0pYLXZ6ZkJmTXMwWTU5MnhCOTYtVW82X0Q4R3h4TWhjQS1VSEN6bFpmVmhyMXlISW9PZXFTSHZKcHFWUEtVenluRUhPMy0xU2lXQVhPMk…

WANBURY — Frequently Asked Questions

What is the current share price of Wanbury Limited (WANBURY)?

As of 2026-09-10 05:11 IST, Wanbury Limited (WANBURY) trades at ₹244.75 on NSE. Its 52-week range is ₹163.34 to ₹344.75.

What is the market capitalisation of WANBURY?

Wanbury Limited (WANBURY) has a market capitalisation of ₹855.82 Cr on NSE.

What is the P/E ratio of WANBURY?

WANBURY trades at a trailing price-to-earnings (P/E) ratio of 15.02. The industry average P/E is 42.46. Its price-to-book (P/B) ratio is 5.07.

What is the return on equity (ROE) of WANBURY?

WANBURY has a return on equity (ROE) of 45.78%. Its return on capital employed (ROCE) is 28.35%.

Is WANBURY a good stock to buy?

This page provides a data-driven analysis of Wanbury Limited (WANBURY), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space